While ESRP1 has been frequently reported as a tumor suppressor in various cancers [15–18], its pro-tumorigenic role has also been shown in some cancers, such as breast and ovarian cancers [13, 14, 19, 20], indicating that ESRP1 plays a dual role in cancer progression depending on the cancer type. Here, ESRP1 is linked to ovarian cancer.